Dr. Shah Discusses Challenges With CAR T-Cell Therapy in Myeloma

Nina Shah, MD
Published: Monday, Jan 14, 2019



Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

The biggest concern 1 year ago was cytokine release syndrome (CRS), says Shah. Although CRS is still commonly seen in approximately 63% of patients, it is relatively well-controlled. Physicians have more experience now—they know when to administer dexamethasone and other agents—and as such, are more comfortable with dealing with it, explains Shah. Concerns over safety have now been replaced with efficacy and durability concerns, she adds.

Another challenge with implementing this therapy into practice has been financial. Physicians are still unsure how much each product is going to cost, who will reimburse it, and who will be eligible to receive reimbursement. Those questions will need to be addressed before research is taken any further, as they play an important role in the accessibility and the applicability of this therapy, concludes Shah.
SELECTED
LANGUAGE


Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

The biggest concern 1 year ago was cytokine release syndrome (CRS), says Shah. Although CRS is still commonly seen in approximately 63% of patients, it is relatively well-controlled. Physicians have more experience now—they know when to administer dexamethasone and other agents—and as such, are more comfortable with dealing with it, explains Shah. Concerns over safety have now been replaced with efficacy and durability concerns, she adds.

Another challenge with implementing this therapy into practice has been financial. Physicians are still unsure how much each product is going to cost, who will reimburse it, and who will be eligible to receive reimbursement. Those questions will need to be addressed before research is taken any further, as they play an important role in the accessibility and the applicability of this therapy, concludes Shah.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x